Hong Kong-listed AI drug developer Insilico Medicine (03696.HK) delivered its first interim results since listing, with revenue hitting $106 million for the first half of 2026, a 287.2% surge year-on-year. The company swung to a net profit of $35.5 million, alongside adjusted earnings of $51.2 million, while operating cash flow also turned positive during the period.

Gross margin expanded to 90.3%, up from 83.8% a year earlier. Management noted this marks the first-ever half-year profit since the company's founding in 2014, driven primarily by a wave of upfront payments from licensing and collaboration deals.

Upfront payments fuel revenue surge

Nearly all revenue for the period came from the drug discovery and pipeline development segment, which generated $103.1 million, making up 97% of total revenue with growth exceeding 300%. The sharp increase was underpinned by the concentrated recognition of upfront fees from multiple out-licensing agreements, including $115 million from Eli Lilly, $32 million from Servier in upfront and recent R&D payments, $18 million from SK Biopharmaceuticals, and $60 million from Takeda Pharmaceutical.

Cumulative business development collaborations have now reached $11 billion historically, with newly announced deals in the first half of 2026 totaling around $7.3 billion. Profitability also benefited from disciplined cost management. Cost of revenue rose 133% to $10.3 million, but that pace lagged far behind the top-line growth, lifting the gross margin to 90.3%. Selling and marketing expenses stood at $6.4 million, R&D costs at $49.3 million, and administrative expenses at $12.6 million, bringing total operating expenses to $68.3 million. Pre-tax profit was $35.8 million, with net profit at $35.5 million.

Clinical pipeline advances amid rising R&D spending

On the flip side of profitability, research investment continues to intensify. R&D spending for the half reached $49.3 million, up 38.7% from a year earlier, reflecting an expanding clinical pipeline, a greater number of early-stage development projects, and higher CRO and staffing costs. The lead candidate ISM001-055 (Rentosertib), being developed for idiopathic pulmonary fibrosis (IPF), entered Phase III trials in China in July 2026. The drug previously demonstrated encouraging Phase IIa results, with patients receiving a 60 mg once-daily dose achieving a +98.4 mL change in forced vital capacity versus a decline of 20.3 mL in the placebo group.

Insilico currently holds 33 preclinical candidates, of which 13 have received IND approval, and 10 programs are in clinical development. Other clinical-stage assets include ISM5411 (Garutadustat) for inflammatory bowel disease, which has started Phase IIa in China; ISM3412, a MAT2A inhibitor for MTAP-deleted cancers, currently in global multicenter Phase I; ISM6331, a TEAD inhibitor for mesothelioma and other solid tumors, also in global Phase I; and ISM8969, an NLRP3 inhibitor for Parkinson's and other neurodegenerative conditions, which has secured IND clearance from China's CDE.

$305 million zero-coupon convertible bond launch

On August 27, the day after the earnings release, Insilico announced plans to issue zero-coupon convertible bonds with a principal amount of $305 million, with Deutsche Bank's Hong Kong branch acting as sole bookrunner. The bonds mature on September 1, 2027, priced at 100% of principal and carrying no interest. The initial conversion price is set at HK$58.07 per share, representing a premium of approximately 23.5% over the August 27 closing price of HK$47.02 on the Hong Kong Stock Exchange and a 32.9% premium over the five-day average closing price of HK$43.70.

If fully converted at the initial price, the bonds would translate into roughly 41.17 million new shares, equivalent to about 7.07% of the issued share capital at the announcement date, or 6.60% on a fully diluted basis. The bonds are slated for listing on Vienna MTF, operated by the Vienna Stock Exchange, while the conversion shares will seek admission on the Hong Kong exchange. The shares will be issued under the general mandate granted by shareholders at the annual general meeting, meaning no separate shareholder approval is required.

Net proceeds are estimated at approximately $301.6 million after deducting commissions and other estimated expenses. The company intends to allocate 40% ($120.7 million) to fund clinical trials for its proprietary candidates, 30% ($90.5 million) to expand its R&D team, 15% ($45.2 million) to support the development and training of frontier scientific foundation models, and the remaining 15% ($45.2 million) for working capital and other corporate purposes.

Prior to this, Insilico completed its Hong Kong initial public offering on December 30, 2025, raising net proceeds of approximately HK$2.026 billion from 94.69 million shares. In January 2026, the full exercise of the over-allotment option added 14.2 million shares, bringing in an additional net amount of about HK$324.5 million. As of June 30, 2026, total net proceeds from the global offering stood at around HK$2.35 billion, of which roughly HK$255 million had been deployed, leaving approximately HK$2.095 billion in reserve.

At the end of the reporting period, the company held bank balances and cash of $357.6 million, term deposits with original maturities exceeding three months of $108.95 million, and financial assets at fair value through profit or loss (primarily money market funds and wealth management products) of $118.25 million. The debt-to-asset ratio was 11.72%, with no material interest-bearing liabilities.

Sustainability of profitability under scrutiny

While the turnaround to profitability is notable, the earnings rely heavily on the concentrated booking of collaboration upfront payments, leaving the stability of the revenue mix as a key market concern. At the results briefing, management indicated that as the number of partnership deals grows, the proportion of upfront payments is expected to gradually decline, while milestone payments should rise, helping to smooth revenue volatility.

The Phase III trial for lead candidate ISM001-055 kicked off in July 2026, with pivotal data anticipated by 2029. Until then, the ultimate validation of the AI drug discovery platform's commercial value remains an open question.